Differences in body fat distribution assessed by ultrasonography in patients receiving antiretroviral drugs

Signorini, Dario José Hart Pontes; Netto, Ana Maria Schmidt de Oliveira; Monteiro, Michelle Carreira Miranda; Signorini, Dario Hart; Codeço, Cláudia Torres; Bastos, Francisco Inácio; Gabbay, Sergio; Andrade, Marion de Fátima Castro de

doi:10.1016/s2255-4823(12)70180-7

Cited by 4 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient self-report on changes in body-fat distribution after HIV infection diagnosis associated with clinician examination was the most common method of lipodystrophy assessment in the studies reviewed (n=6) [18,19,23,[26][27][28] and that showed the greatest variation in prevalence rates, from 38.5% [26] to 67.9% [19]. Other methods used for lipodystrophy diagnosis in these studies were patient selfreport alone (n=4) [17,20,21,28]; clinician diagnosis associated with body measurements (n=1) [22]; patient self-report associated with body measurements (n=2) [30,31]; and clinician diagnosis alone (n=2) [24,25].…”

Section: Synthesis Of Resultsmentioning

confidence: 99%

“…Ceccato et al [24] investigated the association between the incidence of lipodystrophy and dyslipidemia and the longer use of protease inhibitors. Signorini et al [27] evaluated the content of body-fat in HIV-infected individuals according to the duration of HAART, and found that all patients had lipodystrophy after one year of HAART. On the other hand, no patient with less than one year of pharmacological treatment had lipodystrophy.…”

Section: Discussionmentioning

confidence: 99%

“…Not all the surveyed patients developed lipodystrophy associated with HIV [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31], which suggests that lipodystrophy syndrome varies not only with respect to the length of time of the treatment regimen, but also in relation to the effects of systemic chronic inflammatory process resulting from HIV infection itself and factors associated with lifestyle such as physical activity, dietary pattern, and other factors [23,36,37]. There are few studies in the literature comparing these changes with those of non-HIV-infected individuals, because a fat gain can happen with natural aging, or as an immune recovery process after initiation of HAART regimen [38,39].…”

Section: Discussionmentioning

confidence: 99%

“…Table 1 shows the characteristics of the Brazilian studies included in the review with estimates of prevalence of lipodystrophy in people living with HIV. With regard to the study design, 14 were crosssectional studies [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31], and 1 was a retrospective cohort study [19].…”

Section: Study Selectionmentioning

confidence: 99%

“…The remaining papers were intended to assess metabolic changes, and lipodystrophy was a secondary outcome [19][20][21][22][24][25][26][27][28].…”

Section: Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Prevalence of HIV-Associated Lipodystrophy in Brazil: A Systematic Review of the Literature

Justina¹,

Trevisol²,

Schuelter‐Trevisol³

2014

J AIDS Clin Res

View full text Add to dashboard Cite

Section: Synthesis Of Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

“…The remaining papers were intended to assess metabolic changes, and lipodystrophy was a secondary outcome [19][20][21][22][24][25][26][27][28].…”

Section: Study Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence of HIV-Associated Lipodystrophy in Brazil: A Systematic Review of the Literature

Justina¹,

Trevisol²,

Schuelter‐Trevisol³

2014

J AIDS Clin Res

View full text Add to dashboard Cite

Reversibility of Lipoatrophy in HIV-Infected Patients Taking Antiretroviral Therapy: a Cohort Study with Ultrasound Assessment

Zadro

2022

acc

View full text Add to dashboard Cite

The aim of this study was to characterize and compare changes in subcutaneous fat in the malar, brachial and crural region in a cohort of HIV-infected patients taking antiretroviral therapy. This prospective longitudinal study included 77 patients who were selected from the initial cohort evaluated in 2007 and 2008. We examined reversibility of lipoatrophy measured by ultrasound over at least five-year period and factors related to its reversibility. All 46 patients who used stavudine switched from stavudine to another combination. Of 58 patients on zidovudine, 16 (28%) were on a zidovudine based regimen at the second follow up. There was evidence for subcutaneous fat increase in the malar area (p<0.001) and no increase in the brachial and crural areas. Patients who were smokers and had poor adherence to the Mediterranean diet had a thinner malar area at the follow up measurement (p=0.030) and smaller increase in subcutaneous malar fat compared to others (p=0.040). Our study suggested that modest increase of subcutaneous fat in malar area coincided with stopping stavudine and fewer usage of zidovudine. Lifestyle with non-adherence to the Mediterranean diet and smoking were associated with a smaller increase in subcutaneous malar fat.

show abstract

Evaluate the Response Rate of Acute Lymphocytic Leukemia Patients to Hyper Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone Regimen and Remission Rate to Stay Until the End of the Arbitrary Treatment

2018

View full text Add to dashboard Cite

Background:This study aimed to determine the effect of Hyper-Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone (CVAD) in the treatment of acute lymphoblastic leukemia (ALL) patients and remission duration.Materials and Methods:During a cross-sectional study in the Seyed Al-Shohada Hospital in Isfahan, patients with ALL who were admitted and treated from 2011 to 2015 because of the risk of ALL were selected and through the records investigation, demographic information, disease information, treatment, remission duration, current status, and duration of survival were collected in the form of data and are sick after going into remission, including the duration and recurrence remission survival time in treatment were analyzed and consequence, whether the patient is going into remission, remission and relapse and survival time based on the duration of treatment were analyzed.Results:Of the 62 patients, 13 patients after starting of treatment did not go to remission and died, but 49 patients (79%) went into complete remission. 21 of them of Hyper-CVAD group and 28 patients of classical treatment group (75/7% vs. 84%), but the difference was not significant (P = 0.43). Of the 48 patients who had a complete remission with the treatment regimen, ten patients relapsed after treatment with two of them of Hyper-CVAD group and eight patients were in the classical treatment group (9/5% vs. 29/6%), and the difference between the two groups was significant (P = 0.015).Conclusion:Hyper-CVAD regimen resulted in increased survival time of patients with ALL and less disease recurrence and therefore contraindications for use if the existing rules, and under the supervision of treatment, can be used.

show abstract

Differences in body fat distribution assessed by ultrasonography in patients receiving antiretroviral drugs

Cited by 4 publications

References 25 publications

Prevalence of HIV-Associated Lipodystrophy in Brazil: A Systematic Review of the Literature

Prevalence of HIV-Associated Lipodystrophy in Brazil: A Systematic Review of the Literature

Reversibility of Lipoatrophy in HIV-Infected Patients Taking Antiretroviral Therapy: a Cohort Study with Ultrasound Assessment

Evaluate the Response Rate of Acute Lymphocytic Leukemia Patients to Hyper Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone Regimen and Remission Rate to Stay Until the End of the Arbitrary Treatment

Contact Info

Product

Resources

About